Imprimis Pharma to take on Allergan's Restasis with cheaper product

(Reuters) - Shares of Imprimis Pharmaceuticals sky-rocketed as much as 91.1 percent on Thursday, after it said it would offer a cheaper option to Allergan's dry eye disease medicine, Restasis.